If you're living with HIV, a new study just handed your doctor a reason to get more aggressive about your HPV screening — and it handed you a reason to push for it.

What the Study Actually Found

Research published in JAMA Network Open found that both solid organ transplant recipients and people living with HIV face dramatically elevated odds of developing four specific HPV-linked cancers: cervical, oropharyngeal, anal, and vulvar.

Transplant recipients showed the steepest risk jump. Their odds of anal cancer were more than 10 times higher than the general population. People living with HIV weren't far behind — with anal cancer odds running roughly 19 times higher in some analyses.

The mechanism isn't mysterious. Both groups operate with suppressed or altered immune function, which means the body struggles to clear HPV on its own. When HPV lingers, precancerous cells get more time to progress.

Why Anal Cancer Keeps Leading the Numbers

Anal cancer is having a grim statistical moment, and immunocompromised populations are bearing the worst of it.

"People with HIV have a profoundly elevated risk of anal cancer, and yet anal cancer screening is nowhere near as standardized as cervical cancer screening," noted researchers in the study, pointing to a surveillance gap that leaves high-risk patients without a clear protocol.

The disparity is striking. Cervical cancer has a well-worn screening pathway — Pap smears, HPV co-tests, colposcopy. Anal cancer doesn't enjoy the same infrastructure, despite the numbers demanding it.

For people living with HIV who want a fuller picture of what this data means across cancer types, our deep-dive on HPV in men breaks down how HPV-linked anal and oropharyngeal cancers affect people who are often left out of the conversation entirely.

The Immune System Is the Common Thread

Transplant recipients take immunosuppressant drugs deliberately — their survival depends on preventing organ rejection. That same suppression that saves their transplanted kidney also disarms the immune surveillance that would normally catch and eliminate HPV-infected cells before they turn dangerous.

HIV works differently but arrives at the same problem. Without treatment or with a compromised CD4 count, the immune system simply can't do the clearance work. The CDC has long documented that people living with HIV face heightened risk for a range of cancers linked to viral co-infections, and HPV-associated malignancies sit near the top of that list.

This is why antiretroviral therapy matters beyond just viral suppression. Keeping your immune system functional has downstream effects on cancer risk that go well beyond HIV itself.

The HPV Vaccine Gap Nobody Talks About

Here's the thing most people miss: the HPV vaccine — Gardasil 9 — covers seven cancer-causing HPV strains. It works best before exposure, yes, but NIH data supports vaccination up to age 45 for adults who may benefit.

For transplant candidates, vaccination before transplant is considered best practice — but not everyone gets there in time. And for people living with HIV, vaccine uptake remains lower than it should be, even though the benefit is arguably highest in this group.

If you haven't been vaccinated and you're under 45, ask your provider directly. Not as a passive suggestion. Ask with the data from this study in hand.

We've covered the vaccine's track record extensively — the evidence that it nearly eliminates cervical cancer deaths is now hard to argue with. Immunocompromised people deserve that protection even more, not less.

What You Should Do With This Information Right Now

This study isn't a reason to panic. It's a reason to act with more urgency than the healthcare system might be giving you.

If you're living with HIV, ask your provider specifically about anal Pap smears and high-resolution anoscopy — the two tools that exist for anal dysplasia screening. Not every clinic offers them, but enough do that you should be pushing for a referral if they're not already on your radar.

If you've had a solid organ transplant, make sure your transplant team and your primary care provider are talking to each other about cancer surveillance. Too often, those conversations fall into the gap between specialties.

The National Cancer Institute's guidance on HPV and cancer offers a solid starting framework for these conversations with your care team.

And if you want to understand how layering protections — including antivirals and other strategies — can support your overall health when you're managing an STI alongside another condition, our guide on layering protection is worth revisiting.

Here at MeetPositives, we know you're already managing more than most. An HIV diagnosis or a transplant history means you're tracking your health with a level of attention most people never have to develop. Use that same vigilance here. HPV screening for immunocompromised people isn't optional — it's overdue. Get loud with your care team about it, because this data says waiting costs more than asking.